|
|
|
|
| |
|
|
Silva,Giovanni Faria; Polônio,Rodrigo José; Pardini,Maria Inês Moura Campos; Corvino,Silvia Maria; Henriques,Rita Maria Saccomano; Peres,Mari Nilce; Coelho,Kunie Iabuki Rabello. |
The combination of pegylated interferon (PEG-INF) and ribavirin is currently the best treatment for chronic hepatitis C, providing a sustained virological response (SVR) in 54%-63% of patients. In patients infected with hepatitis C virus (HCV) genotype 1, the SVR rate is 42%-52%. To evaluate the treatment efficacy of this drug combination, we conducted an open, prospective study of 58 consecutive treatment-naïve patients infected with HCV genotype 1 and treated at a university hospital, comparing those presenting an SVR (SVRs), nonresponders (NRs), and relapsers (RELs). Among the intent-to-treat patients, an end-of-treatment virological response was achieved in 69% of the sample as a whole and in 52% of the SVRs. We found that being an SVR was... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C; Pegylated interferon alfa 2b; Genotype 1; Relapsers. |
Ano: 2007 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000600006 |
| |
|
|
|